Funder: The Association for Frontotemporal Degeneration
Due Dates: September 30, 2024 (Letter of Intent) | December 9, 2024 (Invited Full Proposal)
Funding Amounts: Up to $2,500,000 over 1–3 years; milestone-based payments; co-funding encouraged.
Summary: Supports early-stage clinical trials for Frontotemporal Dementia (FTD), emphasizing biological mechanisms, biomarkers, and therapeutics for both sporadic and genetic forms.
Key Information: Open to global academic, non-profit, and biotech applicants; device-based interventions require pre-application contact.